Tesamorelin + Ipamorelin
Tesamorelin + Ipamorelin applies the GHRH + GHRP synergy principle using the FDA-approved GHRH analogue Tesamorelin instead of CJC-1295. Tesamorelin is the complete 44-amino-acid GHRH sequence, producing more complete pituitary signalling than the truncated 29-amino-acid CJC-1295. This stack is particularly relevant for visceral fat reduction, metabolic syndrome research, and body composition optimisation where the full GHRH sequence is preferred.
Stack Components
This blend combines 2 research peptides with complementary mechanisms designed to produce synergistic outcomes.
Synergy Rationale
Tesamorelin and Ipamorelin operate through the same GHRH + GHRP synergistic mechanism as CJC-1295 + Ipamorelin, but with Tesamorelin providing the full 44-amino-acid GHRH signal rather than the truncated 29-amino-acid version. Tesamorelin's complete sequence activates additional binding interactions on the GHRH receptor that may produce more complete GH synthesis priming.
Tesamorelin has a unique established track record in visceral fat reduction (FDA-approved for HIV lipodystrophy) that CJC-1295 lacks. For research specifically targeting abdominal/visceral adiposity — a key metabolic risk factor — Tesamorelin's validated mechanism makes it the preferred GHRH analogue component.
Ipamorelin's clean GHSR-1a profile remains the ideal GHRP partner regardless of which GHRH analogue is used. Adding Ipamorelin to Tesamorelin's daily dosing converts the protocol from single-mechanism GH stimulation to the amplified GHRH + GHRP dual-mechanism approach.
Combined Mechanism of Action
Tesamorelin is a synthetic form of the complete human GHRH (1-44) with a trans-3-hexenoic acid modification that prevents DPP-IV degradation. It activates GHRH receptors with the full receptor binding footprint of native GHRH, producing maximal GH synthesis signalling in pituitary somatotrophs.
Ipamorelin activates GHSR-1a to trigger the GH pulse and suppress somatostatin. As with the CJC-1295 version of this stack, the combined effect produces GH pulses that are several-fold larger than either compound alone, while maintaining the pulsatile pattern rather than sustained supraphysiological elevation.
The tesamorelin-specific FDA data on visceral fat reduction (15–18% trunk fat reduction in 26 weeks) represents the clearest clinical proof-of-concept for a GHRH analogue's metabolic effects — validating the downstream body composition impact of GHRH-driven IGF-1 elevation.
Research Evidence
Tesamorelin's Phase 3 FDA approval programme provides robust human data. Ipamorelin's clean profile is well-established. The combination applies validated individual mechanisms.
Tesamorelin Reduces Visceral Adiposity in HIV Lipodystrophy (Phase 3)
Tesamorelin 2mg/day produced 15–18% trunk fat reduction versus placebo at 26 weeks in two Phase 3 trials (n=816), with triglyceride reduction and improved lipid profiles as secondary benefits.
Component Dosing Protocol
Unlike CJC-1295 which is typically dosed 2–3× daily, Tesamorelin is dosed once daily to mirror its clinical protocol. Ipamorelin is added once daily at the same time. Bedtime dosing leverages the nocturnal GH pulse window.
Safety Considerations
Reported Side Effects
- Arthralgia / joint pain (tesamorelin)
- Water retention / oedema
- Injection site redness
- Tingling (Ipamorelin)
- Headache
- Nausea (transient)
Contraindications
- Active malignancy
- Hypothalamic-pituitary disruption
- Pregnancy
- Uncontrolled diabetes
Frequently Asked Questions
Is Tesamorelin + Ipamorelin better than CJC-1295 + Ipamorelin?
Neither is definitively superior. Tesamorelin provides the full 44-AA GHRH signal and has FDA validation for visceral fat reduction. CJC-1295 is more flexible (can be dosed 2–3× daily for more GH pulses) and is more widely used due to lower cost and availability through compounding pharmacies. For research specifically targeting visceral adiposity, Tesamorelin has stronger direct evidence.
How do I administer Tesamorelin and Ipamorelin together?
Tesamorelin and Ipamorelin can be mixed in the same syringe and injected once daily (abdomen is the preferred Tesamorelin injection site). Unlike CJC-1295 which benefits from 2–3× daily dosing, Tesamorelin's clinical protocol is once daily — so Ipamorelin follows the same schedule here. Bedtime dosing aligns with the natural nocturnal GH pulse for optimal output.
Does Tesamorelin improve metabolic syndrome?
Tesamorelin's Phase 3 data in HIV lipodystrophy showed not only 15–18% visceral fat reduction but also improvements in triglycerides, HDL cholesterol, and waist circumference — all core components of metabolic syndrome. Off-label research use in non-HIV metabolic syndrome leverages these established metabolic benefits. The mechanism (GH-driven lipolysis of visceral adipose tissue) is independent of HIV status.
What monitoring is needed on Tesamorelin + Ipamorelin?
Key monitoring: baseline IGF-1 (tesamorelin significantly raises IGF-1), fasting glucose and insulin (GH acutely increases insulin resistance), and triglycerides/lipid panel. IGF-1 should be checked at 8–12 weeks and kept within upper-normal range. Joint pain (arthralgia) and fluid retention are common clinical flags that may indicate the GH signal is too strong and dose reduction is warranted.
Can this stack be used if I have type 2 diabetes?
Use in type 2 diabetes requires caution. GH acutely increases insulin resistance via counter-regulatory mechanisms. In the FDA tesamorelin trials, glucose parameters were monitored closely and those with poorly controlled diabetes were excluded. In well-controlled T2DM with physician supervision, tesamorelin-based protocols have been studied, but glucose management typically requires adjustment during treatment.
Key Research References
- Falutz J et al. (2010). Metabolic effects of tesamorelin in patients with HIV. N Engl J Med.
- Johansen PB et al. (1999). Ipamorelin. Growth Horm IGF Res.
Explore more peptide combination stacks
Browse All Blends →